MY ACCOUNT | NEWSLETTER |

Antimicrobial resistance and prevalence of canine uropathogens at the Western College of Veterinary Medicine Veterinary Teaching Hospital, 2002–2007


Between January 2002 and June 2007, uropathogens were isolated from 473 of 1557 canine urine samples submitted to Prairie Diagnostic Services from the Western College of Veterinary Medicine Veterinary Teaching Hospital. Culture and susceptibility results were analyzed, retrospectively, to estimate the prevalence of common bacterial uropathogens in dogs with urinary tract infections and to identify changes in antimicrobial resistance. The most common pathogens identified were Escherichia coli, Staphylococcus intermedius, Enterococcus spp., and Proteus spp. Antimicrobial resistance increased during the study period, particularly among recurrent E. coli isolates. Using the formula to help select rational antimicrobial therapy (FRAT), bacterial isolates were most likely to be susceptible to gentamicin, fluoroquinolones, amoxicillin-clavulanic acid, and groups 4 and 5 (third generation) cephalosporins.

Introduction

Bacterial urinary tract infection (UTI) is one of the most commonly diagnosed infectious diseases in canine practice and affects approximately 14% of dogs presented for veterinary care. Uropathogenic strains of Escherichia coli are the most common cause of UTIs in both humans and dogs, and strains of this species are often abundant in the gastrointestinal tract at the time of infection. In contrast to most intestinal strains of E. coli, uropathogenic strains possess virulence factors which facilitate survival and persistence in the urinary tract. The risk of UTI recurrence is increased when highly pathogenic bacteria or underlying problems (such as, anatomic abnormalities, neoplasia, diabetes mellitus) are present. Microbiological culture and susceptibility testing is the cornerstone of UTI diagnosis and the results are used by veterinarians to select antimicrobial therapy. Susceptibility results from specific populations are used to select empirical therapy and to monitor trends in antimicrobial resistance. Antimicrobial resistance in uropathogens complicates therapy in dogs and is also a public health concern because these pathogens may be zoonotic.


The epidemiology of human uropathogens varies significantly by region and care setting. Given the many other similarities between human and canine UTIs, there is likely regional and population-specific variation in the epidemiology of canine uropathogens. The prevalence of fluoroquinolone resistance in canine uropathogens is increasing in the United States, but only limited information is available about antimicrobial resistance trends in Canadian isolates.


Multi-drug resistance was observed in canine urinary isolates from an intensive care unit at the Ontario Veterinary College teaching hospital; however, the population of that study may not be representative of the general population of dogs in other areas, such as western Canada. The objectives of this study were to estimate the prevalence of uropathogens in dogs with urinary tract infections at the Western College of Veterinary Medicine Veterinary Teaching Hospital (WCVM-VTH), to apply the formula to help select rational antimicrobial therapy (FRAT) developed by Blondeau and Tillotson, and to identify changes in antimicrobial resistance among canine uro-pathogens over a 5-year period,


Authors: Katherine R Ball, Joseph E Rubin, M Chirino-Trejo, Patricia M Dowling

Source: https://pmc.ncbi.nlm.nih.gov/

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Advancing the 3Rs: innovation, implementation, ethics and society

Like0
Dislike0

Automated Knowledge-Based Radiation Treatment Planning in Canine and Feline Nasal Tumors

Like0
Dislike0

Does Lung Function Imaging Modality Have a Dosimetric Impact On Functional Avoidance Treatment Planning: Assessment Using Prospective Clinical Trial Data

Like0
Dislike0

One Committed and Caring NC State Veterinary Student, So Many Choices

Like0
Dislike0

Dentalis Earns 5 VOHC® Seals, Positioning for Global Expansion in Animal Health

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top